Abirami Sivapiragasam

Clinical trials

• A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)

  Principal investigator · Recruiting · Phase 2

  Medical University of South Carolina

  2026–2030
• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  Site PI · Recruiting · Phase 3

  Eli Lilly and Company

  2025–2033
• ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

  Site PI · Recruiting · Phase 3

  Alliance for Clinical Trials in Oncology

  2025–2037
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

  Site PI · Recruiting · Phase 3

  Stemline Therapeutics, Inc.

  2024–2032